438 related articles for article (PubMed ID: 16580667)
41. IFI16 in human prostate cancer.
Alimirah F; Chen J; Davis FJ; Choubey D
Mol Cancer Res; 2007 Mar; 5(3):251-9. PubMed ID: 17339605
[TBL] [Abstract][Full Text] [Related]
42. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
43. PMEPA1 promotes androgen receptor-negative prostate cell proliferation through suppressing the Smad3/4-c-Myc-p21 Cip1 signaling pathway.
Liu R; Zhou Z; Huang J; Chen C
J Pathol; 2011 Apr; 223(5):683-94. PubMed ID: 21341270
[TBL] [Abstract][Full Text] [Related]
44. Differential expression of integrin subunits in DU-145/AR prostate cancer cells.
Nagakawa O; Akashi T; Hayakawa Y; Junicho A; Koizumi K; Fujiuchi Y; Furuya Y; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2004 Oct; 12(4):837-41. PubMed ID: 15375509
[TBL] [Abstract][Full Text] [Related]
45. Hypoxia increases androgen receptor activity in prostate cancer cells.
Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
[TBL] [Abstract][Full Text] [Related]
46. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
47. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
Bao BY; Hu YC; Ting HJ; Lee YF
Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085
[TBL] [Abstract][Full Text] [Related]
48. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells.
Pajonk F; van Ophoven A; McBride WH
Cancer Res; 2005 Jun; 65(11):4836-43. PubMed ID: 15930304
[TBL] [Abstract][Full Text] [Related]
49. Androgen receptor-mediated repression of novel target genes.
Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
51. Androgen deprivation increases p300 expression in prostate cancer cells.
Heemers HV; Sebo TJ; Debes JD; Regan KM; Raclaw KA; Murphy LM; Hobisch A; Culig Z; Tindall DJ
Cancer Res; 2007 Apr; 67(7):3422-30. PubMed ID: 17409453
[TBL] [Abstract][Full Text] [Related]
52. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
53. Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence.
Xin H; Curry J; Johnstone RW; Nickoloff BJ; Choubey D
Oncogene; 2003 Jul; 22(31):4831-40. PubMed ID: 12894224
[TBL] [Abstract][Full Text] [Related]
54. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.
Laidler P; Dulińska J; Lekka M; Lekki J
Arch Biochem Biophys; 2005 Mar; 435(1):1-14. PubMed ID: 15680901
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
56. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
57. Expression of androgen receptor coactivators in normal and cancer prostate tissues and cultured cell lines.
Mestayer C; Blanchère M; Jaubert F; Dufour B; Mowszowicz I
Prostate; 2003 Aug; 56(3):192-200. PubMed ID: 12772188
[TBL] [Abstract][Full Text] [Related]
58. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
59. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
60. Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines.
Mori S; Murakami-Mori K; Bonavida B
Anticancer Res; 1998; 18(6A):4403-8. PubMed ID: 9891500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
